The distinct roles of the anaphylatoxin receptors C5aR1, C5aR2 and C3aR during experimental invasive meningococcal disease

Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptors

“…Previous studies have suggested that selected ligands exhibit species-specific differences in their pharmacology at C5aR1. 20 Therefore, we first compared the pharmacology of human C5a and C5a pep , a synthetic peptide designed based on the carboxyl-terminal sequence of C5a, on the human and mouse C5aR1, referred to as hC5aR1 and mC5aR1, respectively, in G-protein and βarr assays. We observed that both C5a and C5a pep behave as full agonists on mC5aR1 with slightly lower potency compared with hC5aR1 in terms of G-protein-mediated cAMP response ( Figures 1G and 1H ).…”